MISSISSAUGA, ON, May 2, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2025 after the market close on Thursday, May 8, 2025. The Company will also hold a conference call on Friday, May 9, 2025 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | Friday, May 9, 2025 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBER: | 416-945-7677 or 888-699-1199 |
REPLAY: | 289-819-1450 or 888-660-6345 Code: 69080# |
Expires: May, 16, 2025 | |
WEBCAST: |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$14.48 |
| Daily Change: | 0.03 0.21 |
| Daily Volume: | 17,609 |
| Market Cap: | C$367.650M |
August 07, 2025 May 08, 2025 April 29, 2025 November 07, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
